U.S. market Closed. Opens in 57 minutes

HROWL | Harrow Health, Inc. 8.625% Senior Notes due 2026 Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 25.30 - 25.40
52 Week Range 22.05 - 25.73
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 2,335
Average Volume 4,345
Shares Outstanding 64,009,548
Market Cap 1,619,441,564
Sector Healthcare
Industry Medical - Pharmaceuticals
IPO Date 2021-05-07
Valuation
Profitability
Growth
Health
P/E Ratio N/A
Forward P/E Ratio N/A
EPS N/A
1YR Price Target N/A
Dividend Yield 8.52%
Dividend Per Share 2.16
Dividend ExDate N/A
Dividend PayDate N/A
Employees 217
Country USA
Website HROWL
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
*Chart delayed
Analyzing fundamentals for HROWL we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is passable. For more detailed analysis please see HROWL Fundamentals page.

Watching at HROWL technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on HROWL Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙